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INTRODUCTION 
 
Critically ill patients in the intensive care unit 
(ICU) are exposed to multiple risk factors 
that increase the likelihood of damage to their 
motor unit. Fluid and electrolyte 
disturbances, catabolic stressors, nutritional 
deficiency, and medications collectively 
increase the risk for neuromuscular damage, 
consequently prolonging hospital stay, 
delaying recovery, and increasing morbidity 
and mortality.1 The most common causes of 
neuromuscular weakness in the ICU patients 
are critical illness neuropathy and critical 
illness myopathy, which usually present as 
failure to wean off from the ventilator and 
decreased limb movements.2 The incidence 
rate for acquiring weakness from critical 
illness neuropathy (CIN) and critical illness 
myopathy (CIM) has drastically increased, 
and it is twice as common as primary 
neuromuscular causes, such as Guillain-
Barre syndrome (GBS) and motor neuron 
diseases.2 Early diagnosis and prompt 
treatment are necessary as complications, 
such as ventilatory failure and aspiration 
pneumonia significantly increase morbidity 
and mortality.  
 
CLASSIFICATION 
 
Although there are multiple causes for 
generalized weakness in an ICU patient, 
motor weakness can be broadly classified as 
due to: 
 
● Preexisting neuromuscular 
disorders  
● Neuromuscular complications of 
critical illness 
 
Motor weakness can be further localized to 
the anatomical site of involvement of a 
disease process (Table 1). 
 
PREEXISTING NEUROMUSCULAR 
DISORDERSS 
 
Spinal cord disorders 
Motor weakness due to spinal cord disorders 
can be further classified into compressive and 
non-compressive myelopathy. The most 
common cause for non-compressive 
myelopathy is transverse myelitis. 
Transverse myelitis is mostly idiopathic or 
post-infectious secondary to an infection with 
a virus (cytomegalovirus, herpes simplex 
virus, Coxsackie), or bacteria (Mycoplasma, 
Legionella). Other causes include: multiple 
sclerosis, Devic’s disease, and collagen 
vascular disease.3 
Transverse myelitis can be diagnosed 
upon a high clinical suspicion as it 
characteristically presents with bilateral signs 
and symptoms, and a clearly demarcated 
sensory level with progression period ranging  
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Table 1. Causes of generalized weakness in ICU and their anatomical localization 
 
Localization  Preexisting Neuromuscular 
Disorder 
Complication of Critical illness 
Spinal cord Trauma  
Infarction 
Transverse myelitis 
Unknown 
Anterior horn cell Amyotrophic lateral sclerosis (ALS) 
Poliomyelitis 
Hopkins syndrome 
Peripheral nerve GBS 
Chronic inflammatory 
demyelinating polyneuropathy 
Critical illness polyneuropathy 
Neuromuscular junction Myasthenia gravis 
Lambert-Eaton syndrome 
Botulism 
Prolonged neuromuscular blockade 
Muscle Muscular dystrophy 
Polymyositis 
Metabolic/congenital 
Mitochondrial 
Critical illness myopathy 
 
from hours to weeks.4 Cerebrospinal fluid 
(CSF) shows characteristic pleocytosis or 
high immunoglobulin levels, and an MRI 
shows increased segmental contrast 
enhancement.5  
Spinal cord infarction is a known 
complication of: aorto-iliac occlusion, aortic 
dissection, and aortic surgeries. It can also be 
secondary to cardiac arrest and global 
hypotension.6  
The standard care of treatment for 
transverse myelitis includes intravenous 
corticosteroids, such as methyl prednisone or 
dexamethasone, which helps in reducing 
spinal cord swelling and inflammation.7 
Plasma exchange can be tried in refractory 
cases.  
 
Anterior Horn Cell Disorders 
Amongst anterior horn cell disorders, 
amyotrophic lateral sclerosis (ALS) is a well-
known culprit causing respiratory weakness 
due to primary phrenic motor neuron 
involvement.8 ALS presents with 
characteristic simultaneous upper and lower 
motor neuron involvement. Most common 
presenting symptoms include weakness, 
atrophy, fasciculations, difficulty 
swallowing, and slurred speech.9 The disease 
is usually relentlessly progressive with death 
occurring in 50% of cases within 3 years and 
in 80% of cases within 5 years.9 The most 
common complication encountered in ALS 
patients in the ICU is aspiration pneumonia 
secondary to respiratory failure, which 
almost always requires tracheostomy and/or 
percutaneous endoscopic gastrostomy (PEG) 
tube placement.10 Electrophysiological study 
is the preferred method of investigation and 
reveals widespread denervation on 
electromyography (EMG). 
 
Peripheral Nerve Disorders 
Amid the peripheral nerve disorders, GBS is 
well known to cause weakness. GBS usually 
occurs weeks after a flu-like or diarrheal 
illness caused by infectious agents, such as 
cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), Herpes Simplex virus (HSV), 
Mycoplasma, Chlamydia and/or 
  
 
AJHM Volume 1 Issue 3 (Jul-Sept 2017)        REVIEW ARTICLE 
 
Katyal et al. www.ajhm.org 2 
Campylobacter.11 Weakness follows a 
characteristic pattern of a rapidly progressive 
ascending motor and sensory paralysis, 
which later progress to respiratory weakness 
and bulbar involvement.12 Also commonly 
seen is the autonomic involvement that 
presents as postural hypotension, fluctuation 
in blood pressure and cardiac dysrhythmias.12  
Respiratory paralysis is the most 
common indication for an ICU admission.12 
The characteristic lab finding in GBS is CSF 
albuminocytological dissociation, which 
usually occurs 48 hrs after onset of the 
illness.13 Electrodiagnostic studies show 
slowing of nerve conduction velocity. 
Management of GBS in an ICU setting is 
governed by two parameters: vital capacity 
(VC) and arterial blood gas (ABG).14 
Intubation is recommended in patients with:  
VC <12-15 ml/kg, falling VC, and retained 
secretions. The recommended treatment 
options are intravenous immunoglobulin 
(IVIG) or plasma exchange. Plasmapheresis 
is usually recommended in patients unable to 
ambulate, worsening forced vital capacity, 
bulbar muscle involvement, and in those 
requiring intubation and ventilation. Five 
sessions of plasma exchange over 10-14 days 
is recommended with exchange of a total of 
200 mL of plasma/ kg of body weight.14  
IVIG in dose of 2 g/kg divided over 5 
consecutive days is the recommended 
treatment.14 Combination therapy of IVIG 
and plasma exchange is not recommended 
and has no added benefits over individual 
treatment. Steroids are not helpful in 
treatment of GBS in ICU patients.15  
 
Neuromuscular Junction Disorders 
The most common myasthenic syndrome 
encountered in an ICU includes myasthenia 
gravis (MG) and Lambert-Eaton myasthenic 
syndrome. The underlying defect in 
myasthenia gravis is a decreased number of 
available acetylcholine receptors (AChRs) at 
the neuromuscular junction, secondary to an 
antibody mediated immune destruction, 
which compromises the neuromuscular 
conduction and presents as motor 
weakness.16 The distribution of muscle 
weakness has a characteristic involvement of 
extraocular, facial, bulbar and later 
respiratory muscles, which usually presents 
as diplopia, dysphagia, and dysarthria.16  
Myasthenic crisis is the most 
common reason for an ICU admission in 
patients with MG. Myasthenia crisis is 
associated with respiratory compromise. It 
presents as respiratory muscle insufficiency, 
and/or inability to handle excessive oral and 
respiratory secretions that require intubation 
and mechanical ventilation.16  
The most common precipitants of an 
MG crisis include intercurrent infections, 
aspiration, sepsis, surgical procedures, 
medications, and pregnancy.16 About 30-
70% of seronegative myasthenic patients 
may have an antibody directed against 
Muscle specific tyrosine kinase (MuSK). 
Such patients tend to have severe disease and 
high frequency of respiratory crises 
compared to an AChR antibody positive 
patients.17  
A vital capacity of less than 1 liter (or 
<20-25 ml/kg), or a negative inspiratory 
factor (NIF) <20 cm of H2O, indicates 
significant respiratory weakness; both 
measurements are commonly used to define 
myasthenic crisis.18 Between 66%-90% of 
patients with an MG crisis require intubation, 
mechanical ventilation, and ICU 
management of the complications.19 IVIG 
and plasma exchange are the mainstay of 
treatment in crisis patients. A typical course 
of IVIG is 400 mg/kg daily for 5 days.20 Five 
rounds of plasma exchange every alternative 
day for 10 days is the standardized therapy.21 
Prednisone can also be used in conjunction 
with IVIG and plasma exchange. 
High rate rapid nerve stimulation 
studies and PQ type anti-voltage gated 
calcium channel antibodies are the standard 
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investigations for diagnosis of Lambert Eaton 
syndrome that responds well to IVIG.22 
Botulism and tick paralysis are 
amongst the uncommon neuromuscular 
junction disorders encountered in an ICU. 
Botulism presents with flaccid paralysis, 
areflexia, and autonomic disturbances. Early 
diagnosis is imperative as early antitoxin 
therapy is associated with decreased hospital 
stay, morbidity, and mortality.23 Mechanical 
ventilation is the mainstay of treatment. Tick 
paralysis is associated with areflexia, 
ascending motor paralysis and preserved 
sensations; a careful search and removal of 
the tick aids in rapid resolution of 
symptoms.24  
 
Muscle Disorders 
Inflammatory myopathies commonly 
encountered in the ICU are dermatomyositis 
and polymyositis. Both present with 
proximal muscle weakness and pain.25 
Dermatomyositis has characteristic skin 
lesions, such as purplish periorbital 
(heliotrope) rash that spreads to the back, the 
neck - Shawl sign, and over the knuckles - 
Gottron’s sign.25 Dermatomyositis is also 
more commonly associated with 
malignancies. The initial investigation for 
diagnosis involves CK levels; definitive 
diagnosis can be made by muscle biopsy and 
an H&E stain. Steroids are the mainstay of 
treatment for inflammatory myopathies.25  
 
NEUROMUSCULAR 
COMPLICATIONS OF CRITICAL 
ILLNESS 
 
ICU acquired neuromuscular weakness is a 
major cause of morbidity in critically ill 
patients. It significantly affects the overall 
prognosis and increases the length of 
hospitalization. The three most common 
causes of an acquired neuromuscular 
weakness in the ICU patients are: critical 
illness polyneuropathy (CIP), critical illness 
myopathy (CIM), and prolonged 
neuromuscular blockade.26 Both, CIP and 
CIM, present as symmetrical, diffuse, flaccid 
muscle weakness affecting extremities and 
diaphragm with a relative sparing of the 
cranial nerves.26 Multiple possible factors 
play a role in the development of 
neuromuscular weakness in critically ill 
patients. The major ones are: systemic 
inflammatory response syndrome (SIRS), 
corticosteroid use, and neuromuscular 
blocking agents.26                            
                     Figure 1. Pathogenesis of development of critical illness polyneuropathy/myopathy in ICU 
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Critical Illness Polyneuropathy 
CIP usually presents as a sensorimotor axon 
loss polyneuropathy, which in an early course 
affects distal muscles more than proximal; 
later it progresses to generalized muscle 
weakness with absent reflexes.27 Most 
patients have concomitant encephalopathy 
due to an underlying sepsis and/or organ 
failure.28 Hyperglycemia, hypoalbuminemia, 
and parenteral nutrition are also known 
exacerbating factors for the development of 
CIP.28 An impaired microcirculation due to 
inflammatory responses leads to a decreased 
nerve perfusion resulting in nerve hypoxia.29 
The earliest clinical suspicion arises when it 
is difficult to wean the patient off of the 
ventilator; other common presentations 
include tetraplegia and absent deep tendon 
reflexes.30 The severity is proportional to the 
length of an ICU stay. 
The most important diagnostic test is 
the electrodiagnostic study. The nerve 
conduction velocities may be normal or 
reduced, but the amplitude of sensory and 
motor responses is significantly decreased or 
even absent.31 Features of acute denervation, 
such as fibrillation, positive sharp waves, and 
reduced recruitment are evident on needle 
electrode studies.31 Nerve biopsy shows 
severe axonal degeneration of motor and 
sensory fibers primarily affecting distal 
segments.31 
The treatment usually comprises of an 
aggressive management of SIRS and 
supportive measures, such as fluid 
resuscitation, antibiotic therapy, and early 
physical therapy. Recovery usually occurs 
over weeks to months. Long term prognosis 
depends upon severity of the underlying 
disease process. 
 
Critical Illness Myopathy 
CIM is the major contributor of an ICU 
related neuromuscular weakness. CIM 
usually develops in patients who are on 
prolonged high dose steroid treatment and/or 
neuromuscular blocking agents.31 It 
characteristically presents as diffuse 
weakness affecting both limbs, distal muscles 
more than proximal. Facial and sometimes 
ocular muscle involvement can be seen.27  
Myosin loss is the hallmark finding of 
CIM. Corticosteroid use causes myosin loss, 
which is further triggered by the common use 
of neuromuscular blockade agents in ICU 
settings.31  
CIM can be further sub-classified as 
thick filament myopathy, catabolic 
myopathy, and acute necrotizing myopathy 
of intensive care.32 An elevated creatine 
kinase (CK) is observed in all types of CIM 
and it is a hallmark feature of the illness. 
Electrodiagnostic studies play a significant 
role in the diagnosis of CIM. Nerve 
conduction studies exhibit low amplitude or 
even absent motor responses, whereas 
sensory responses are preserved.31 Needle 
EMG studies show short duration, polyphasic 
and low amplitude motor unit action 
potentials.31 Muscle biopsy shows muscle 
fiber necrosis, atrophy and regeneration 
mostly affecting type II fibers in absence of 
any inflammatory marker. The hallmark 
finding is a selective loss of the thick filament 
(myosin) in absence of the thin filament 
(actin).31  
Management is usually conservative. 
Discontinuation of steroids and 
neuromuscular blockade agent is 
recommended. There is growing evidence in 
support of using intensive insulin therapy for 
reducing the incidence of both, CIM and 
CIP.33 Prognosis usually depends upon the 
severity of the illness. 
 
Neuromuscular Blockade 
Competitive non-depolarizing 
neuromuscular blocking agents (NMBs), 
such as pancuronium and vecuronium, as 
well as newer benzylisoquinolinium NMBs 
like atracurium and cisatracurium are used 
extensively in ICU settings to aid in 
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mechanical ventilation. Prolonged 
neuromuscular blockade by drugs, electrolyte 
disturbances and metabolic acidosis act 
synergistically with sepsis and SIRS in 
pathogenesis of CIM and CIP.34  
 
CONCLUSION 
 
Multiple predisposing factors are responsible 
for the development of neuromuscular 
weakness in a critically ill patient. Thorough 
history and physical examination is 
paramount and should not be omitted despite 
that the majority of patients are unresponsive, 
confused or sedated. A comprehensive 
investigation protocol should be followed in 
all cases of weakness in ICU settings. The 
spectrum of neuromuscular diseases 
encountered in ICUs nowadays has rapidly 
evolved over the last decades. Early 
diagnosis and prompt treatment is necessary 
to reduce morbidity and mortality in critically 
ill patients and reduce the skyrocketing 
health care expenses.  
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